DRY
EYE DEFINED: INTERNATIONAL DEFINITION AND CLASSIFICATION
OF DRY EYE DISEASE ANNOUNCED
download
press release
BOSTON, MA, May 22, 2007- The Tear Film & Ocular
Surface Society (“TFOS”) presented the findings
of the International Workshop on the Definition, Diagnosis
and Classification of Dry Eye Disease.
The Dry Eye
WorkShop (“DEWS”, dews), sponsored
by TFOS, was created to provide an evidence-based critical
review and summary of the classification, epidemiology,
diagnosis, techniques of basic and clinical research,
and management of dry eye disease.
“This report is conceived to
be an unbiased document offering a global definition
of dry eye disease. It is intended to be a stimulus
for future dry eye research by Industry and the research
community,” said Dr. David A. Sullivan, TFOS President,
Senior Scientist, Schepens Eye Research Institute/Harvard
Medical School and a DEWS Co-Organizer. “While
commercial products are discussed in the report, no
individual product is endorsed by TFOS. Moreover, all
DEWS members were required to provide financial disclosure
statements to ensure the credibility of the report.”
The workshop comprised of 70 experts
from 12 countries. This three-year project culminated
in a report that represents contemporary understanding
and informed conclusions about dry eye disease. “Dry
eye disease is a chronic, progressive disease that afflicts
approximately 40-60 million people in the United States
and 100 million worldwide,” noted Dr. Michael
A. Lemp, Clinical Professor of Ophthalmology, Georgetown
University and DEWS Co-Organizer. “Furthermore,
according to the 2003 Morgan Stanley Dry Eye Report,
in the United States, diagnosis rates are estimated
to be less that 20% of the dry eye patient population.”
The DEWS report addresses the following
areas: Definition & Classification, Diagnosis, Epidemiology,
Clinical Trials, Research, and Management & Therapy.
“These topics build upon a NEI/Industry
Workshop of the early 1990's, and will be of great appeal
to basic scientists, clinical researchers and industry
representatives with an interest in the cornea and external
disease,” stated Anthony J. Bron, Professor Emeritus,
Oxford University and DEWS Chair and Co-Organizer. “We
undertook this project now because there was a critical
need to redefine dry eye disease using current, evidence-based
data.”
The DEWS report was published by The
Ocular Surface and distributed to scientists and clinicians
worldwide. A downloadable version of the document and
additional material is available on the TFOS website:
www.TearFilm.org. Translations of the report will be
offered in numerous languages, including Spanish, French,
Chinese, German, Italian and Japanese.
About the
Tear Film & Ocular Surface Society
TFOS, incorporated in 2000, is an international
non-profit organization headquartered in Boston, MA.
TFOS is dedicated to advancing the research, literacy
and educational aspects of the scientific field of the
tear film and ocular surface. TFOS reaches out to basic
scientists, academic clinicians and industry representatives
originating from more than 80 countries. TFOS organizes
and coordinates international conferences, workshops
and seminars, and promotes research collaborations,
to help achieve their educational mission. More information
about the Society can be found on the TFOS web site
at www.TearFilm.org.
Note to Editors: Please note that TFOS
has received financial support from many companies,
including Alcon, Allergan, Advanced Medical Optics,
Bausch & Lomb, CIBA Vision, Inspire Pharmaceuticals,
McNeil Consumer Healthcare, Novartis, Pfizer, Santen,
SIFI, Vistakon, OcuSense, Senju Pharmaceutical, SOOFT
Italia, Kowa, Otsuka, Alimera, Tomei, Nidek, Laboratoires
Théa and Novagali.
|